{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:54:59Z","timestamp":1761468899595,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.transci.2020.102897","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T03:06:31Z","timestamp":1596683191000},"page":"102897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series"],"prefix":"10.1016","volume":"59","author":[{"given":"Rita Carlotta","family":"Santoro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Gagliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Francesca","family":"Mansueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Calafiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2020.102897_bib0005","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Hemophilia"},{"issue":"5","key":"10.1016\/j.transci.2020.102897_bib0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40272-018-0307-z","article-title":"Prevention and management of bleeding episodes in children with hemophilia","volume":"20","author":"Ljung","year":"2018","journal-title":"Paediatr Drugs"},{"year":"2018","series-title":"Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products","key":"10.1016\/j.transci.2020.102897_bib0015"},{"key":"10.1016\/j.transci.2020.102897_bib0020","first-page":"575","article-title":"Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy","volume":"12","author":"Rocino","year":"2014","journal-title":"Blood Transfusion"},{"key":"10.1016\/j.transci.2020.102897_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)","volume":"11","author":"Manco-Johnson","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2020.102897_bib0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2020.102897_bib0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fmed.2019.00261","article-title":"Status of recombinant factor VIII concentrate treatment for hemophilia a in Italy: characteristics and clinical benefits","volume":"6","author":"Schiavoni","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.transci.2020.102897_bib0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/2040620718777903","article-title":"BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review","volume":"9","author":"Mahlangu","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.transci.2020.102897_bib0045","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2020.102897_bib0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2020.102897_bib0055","first-page":"314","article-title":"Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future","volume":"12","author":"Jimenez-Yuste","year":"2014","journal-title":"Blood Transfus"},{"issue":"4","key":"10.1016\/j.transci.2020.102897_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6040039","article-title":"Outcome of clinical trials with new extended half-life FVIII\/IX concentrates","volume":"6","author":"Mancuso","year":"2017","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.transci.2020.102897_bib0065","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/hae.12691","article-title":"Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII","volume":"21","author":"Shah","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2020.102897_bib0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1160\/TH03-10-0643","article-title":"Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation","volume":"93","author":"Kreuz","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2020.102897_bib0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1538-7836.2009.03650.x","article-title":"Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2020.102897_bib0080","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0037-1613925","article-title":"Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: International Kogenate-FS Study Group","volume":"83","author":"Abshire","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2020.102897_bib0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1538-7933.2004.00646.x","article-title":"Human recombinant DNA-derived antihemophilic factor in treatment of previously untreated patients with hemophilia: final report on a hallmark clinical investigation","volume":"2","author":"Lusher","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2020.102897_bib0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2020.102897_bib0095","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/hae.13148","article-title":"BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics","volume":"23","author":"Garger","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2020.102897_bib0100","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/hae.12952","article-title":"Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial","volume":"22","author":"Saxena","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2020.102897_bib0105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/DDDT.S188171","article-title":"Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81-8973 compared with other full-length rFVIII products","volume":"13","author":"Teare","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.transci.2020.102897_bib0110","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-016-0492-2","article-title":"Improved pharmacokinetics with BAY 81-8973 versus antihemophilic factor (recombinant) plasma\/albumin-free method: a randomized pharmacokinetic study in patients with severe hemophilia A","volume":"56","author":"Shoah","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transci.2020.102897_bib0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jth.12828","article-title":"Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)","volume":"13","author":"Kavakli","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.transci.2020.102897_bib0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13397","article-title":"Individualized PK-based prophylaxis in severe hemophilia","volume":"24","author":"Dargaud","year":"2018","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.transci.2020.102897_bib0125","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1055\/s-0035-1552563","article-title":"Individualizing factor replacement therapy in severe hemophilia","volume":"41","author":"Carcao","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2020.102897_bib0130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1538-7836.2011.04566.x","article-title":"Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers","volume":"10","author":"Tagliaferri","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2020.102897_bib0135","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1182\/blood-2013-11-453159","article-title":"Cardiovascular risk in patients with hemophilia","volume":"123","author":"Kamphuisen","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2020.102897_bib0140","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1111\/hae.12647","article-title":"Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII","volume":"21","author":"Montalvao","year":"2015","journal-title":"Haemophilia"},{"issue":"24","key":"10.1016\/j.transci.2020.102897_bib0145","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2016-11-750885","article-title":"Biological considerations of plasma-derived and recombinant factor VIII immunogenicity","volume":"129","author":"Lai","year":"2017","journal-title":"Blood"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220302093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220302093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:51:06Z","timestamp":1761468666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050220302093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1473050220302093"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2020.102897","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2020.102897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102897"}}